Pioneering Separations Company Quad Technologies Set To Revolutionize Cell Isolation Following Successful Investment
Quad Technologies Inc., developer of a novel separation technology, has announced its entry into the cell separation market. Focused on overcoming barriers associated with conventional cell purification techniques, the company boasts remarkable scientific expertise, a wealth of business experience and comprehensive financial backing. Led by visionary CEO Dr Sean Kevlahan, the company is currently building on successful manufacturing and feasibility studies of QuickGel, its lead patent-pending technology.
Quad Technologies is set to have initial major impact in the multimillion dollar market of cell separation, addressing the growing frustration amongst researchers with the low viability and efficiency of conventional techniques. These techniques can cause modifications to the cell structure and render it unviable for further development, and can have significant time and cost implications. Quad Technologies’ ground-breaking QuickGel is a dissolvable hydrogel technology that, for the first time, allows researchers to maintain the viability and phenotype of rare isolated cells. The company sees additional near term opportunities in protein purification and nucleic acid extraction.
“With our QuickGel technology in hand, Quad is poised for an exciting period of aggressive growth”, commented CEO, Sean Kevlahan who developed the technology while undertaking his PhD at Northeastern University. “Recent validation of our technology at world class beta test sites affords us great confidence in our go-to market strategy. We are looking forward to seeing the impact of our high value cell separation technology in areas such as stem cell research. Having already been widely published, the product is due to be made available later this year and we expect that it will enable major scientific breakthroughs to be achieved...”
Dr Jeffrey Chalmers, Director of the Ohio State University Medical School Cell Separation Core Facility and Professor of Chemical Engineering, who is a member of Quad Technologies’ scientific advisory board explained: “The initial testing of the QuickGel coated beads that we carried out for Quad Technologies clearly demonstrated the capabilities of the technology in overcoming previously unresolvable issues associated with conventional cell isolation techniques. QuickGel will enable developers of the new generation of therapeutics and diagnostics to achieve higher efficiency, cell viability and purity and I am extremely excited to be involved with the company at this time.”
Related News
-
News Understanding the Benefits and Advances of Cleanroom Technology
In an industry where precision and sterility are crucial concerns, cleanrooms play a vital role in maintaining the integrity of pharmaceutical products like drugs, vaccines, and other medical products. So, what is a cleanroom?
-
News AbbVie secures GBP£1.2 billion deal for Gilgamesh’s psychedelic programme
AbbVie has penned a significant agreement to acquire the bretisilocin programme from Gilgamesh Pharmaceuticals for up to £1.2 billion, marking a bold step in the pharmaceutical giant's quest to develop treatments for psychiatric disorders. -
News Gates Foundation commits US$2.5 billion to women’s health research
The Bill & Melinda Gates Foundation has announced a substantial US$2.5 billion commitment to accelerate research and development focused exclusively on women's health through 2030.
-
News Mid-year review: notable FDA drug approvals of 2025
As we fly past the halfway point of 2025, the pharmaceutical landscape reliably continues to evolve with innovative therapies addressing critical medical needs. The FDA has already approved 17 groundbreaking medications this year, each representin... -
News US FDA announces new priority vouchers for accelerated review times
The US FDA announced a new priority program for drug developers – the Commissioner’s National Priority Voucher (CNPV) program aims to enhance the health interests of the US by allowing drug developers to redeem a voucher, shortening th... -
News Google-backed start-up raises US$600 million to support AI drug discovery and design
London-based Isomorphic Labs, an AI-driven drug design and development start-up backed by Google’s AI research lab DeepMind, has raised US$600 million in its first external funding round by Thrive Capital. The funding will provide further power t... -
News AstraZeneca to invest US$2.5 billion in Beijing R&D centre
Amid investigations of former AstraZeneca China head Leon Wang in 2024, AstraZeneca have outlined plans to establish its sixth global strategic R&D centre in China. Their aim is to further advance life sciences in China with major research and manufact... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience.